Abstract
Objective MR-guided Laser Interstitial Thermal Therapy (LiTT) is a minimally invasive surgical procedure for intractable mesial temporal epilepsy (mTLE). LiTT is safe and effective but seizure outcomes are highly variable due to patient variability, suboptimal targeting, and incomplete ablation of epileptogenic zone. Apparent Diffusion Coefficient (ADC) is an MRI sequence that can identify potential epileptogenic foci in the mesial temporal lobe to improve ablation and seizure outcome. The objective of this study was to investigate whether ablation of tissue clusters with high ADC values in the mesial temporal structures is associated with seizure outcome in mTLE after LiTT.
Methods Thirty mTLE patients who underwent LiTT at our institution were analyzed. Seizure outcome was categorized as complete seizure freedom (ILAE Class I) and residual seizures (ILAE Class II – VI). Volumes of hippocampus and amygdala were segmented from preoperative T1 MRI sequence. Spatially distinct hyperintensity clusters were identified in the preoperative ADC map. Percent cluster volume and number ablated were associated with seizure outcomes.
Results The mean age at surgery was 36.6 years and mean follow-up duration was 1.9 years. Proportions of hippocampal cluster volume (35.20% vs. 16.5 %, p = 0.014) and cluster number (27.1 % vs 4.2 %, p = 0.0007) ablated were significantly higher in patients with seizure freedom. For amygdala clusters, only proportion of cluster number ablated was significantly associated with seizure outcome (13.2 % vs. 0 %, p = 0.016). Ablation of hippocampal clusters predicted seizure outcome, both by volume (AUC = 0.7679) and number (AUC = 0.8086) ablated.
Significance Seizure outcome after LiTT in mTLE patients was significantly associated with the extent of cluster ablation in the hippocampus and amygdala. The results suggest that preoperative ADC analysis may help identify high-yield pathological tissue clusters that represent epileptogenic foci. ADC based cluster analysis can potentially assist ablation targeting and improve seizure outcome after LiTT in mTLE.
Competing Interest Statement
William S. Anderson sits on Advisory Boards for Longeviti Neuro Solutions, and NeuroLogic. He is also a paid consultant for Globus Medical. Other authors report no disclosures.
Funding Statement
Not applicable
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Johns Hopkins School of Medicine gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
No data produced in the present work are publicly available.
